Safety Profile of Intravenous Bisphosphonates

Seminars in Oncology

Volumn 34, Issue SUPPL. 4, 2007, Pages

  Mehrotra, Bhoomi ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CREATININE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; ARTICLE; BONE METASTASIS; BONE NECROSIS; CANCER CLASSIFICATION; CANCER RISK; CLINICAL TRIAL; CREATININE CLEARANCE; DEBRIDEMENT; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HUMAN; KIDNEY FUNCTION; PALLIATIVE THERAPY; PATHOLOGIC FRACTURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SPINAL CORD COMPRESSION;

BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INJECTIONS, INTRAVENOUS; JAW DISEASES; KIDNEY DISEASES; OSTEONECROSIS;

EID: 36549075616     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.10.007     Document Type: Article

References (27)

1. Berenson J.R. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 10 (2005) 52-62
2. Conte P., and Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 9 suppl 4 (2004) 28-37
3. Badros A., Weikel D., Salama A., et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 24 (2006) 945-952
4. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 23 (2005) 8580-8587
5. Migliorati C.A., Siegel M.A., and Elting L.S. Bisphosphonate-associated osteonecrosis: A long-term complication of bisphosphonate treatment. Lancet Oncol 7 (2006) 508-514
6. Weitzman R., Sauter N., Eriksen E.F., et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 62 (2007) 148-152
7. Mehrotra B., and Ruggiero S. Bisphosphonate complications including osteonecrosis of the jaw (2006), American Society of Hematology Education Program Book 356-360 Hematology January
8. Mehrotra B. Bisphosphonate complications including osteonecrosis of the jaw [oral presentation] (2006) Presented at the 48th Annual Meeting of the American Society of Hematology, Orlando, FL, December 9-12
9. Mehrotra B. Bone integrity in cancer survivors. [oral presentation] (2007) Presented at the 43rd Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 1-5
10. Hoff A.O., Toth B.B., Altundag K., et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy [poster] (2006) Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2-6
11. Durie B.G.M., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353 (2005) 99-102
12. Pozzi S., Marcheselli R., Sacchi S., et al. Analysis of frequency and risk factors for developing bisphosphonate associated osteonecrosis of the jaw. Blood 106 suppl (2005) (abstr 5057)
13. Dimopoulos M.A., Kastritis E., Anagnostopoulos A., et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Hematologica 91 (2006) 968-971
14. Tosi P., Zamagni E., Cangini D., et al. Bisphosphonates and osteonecrosis of the jaws: Incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zoledronic acid. Blood 106 suppl (2005) (abstr 3461)
15. Cafro A.M., Barbarano L.A., Andriani A., et al. Osteonecrosis of the jaw associated with chronic bisphosphonates therapy: An Italian experience. Blood 106 suppl (2005) (abstr 5152)
16. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22 (2007) 1479-1491
17. Lipton A., Dewar R., Conte P., et al. Long-term safety of zoledronic acid for the treatment of patients with breast cancer and bone metastases [poster] (2004) Presented at the 4th European Breast Cancer Conference, Hamburg, Germany, March 16-19, (abstr 296)
18. Body J.J., Diel I.J., Tripathy D., et al. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: Phase III trial results. Eur J Cancer Care (Engl) 15 (2006) 299-302
19. Desikan R., Veksler Y., Raza S., et al. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol 119 (2002) 496-499
20. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (2002) 1458-1468
21. Rosen L.S., Gordon D.H., Dugan Jr. W., et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100 (2004) 36-43
22. Kohno N., Aogi K., Minami H., et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23 (2005) 3314-3321
23. Rosen L.S., Gordon D., Kaminski M., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 98 (2003) 1735-1744
24. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879-882
25. Saad F., Gleason D., Murray R., et al. Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone [poster] (2003) Presented at the American Urological Association Annual Meeting; Chicago, IL, April 26-May 1, (abstr 1472)
26. Rosen L.S., Gordon D., Tchekmedyian N.S., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial. Cancer 100 (2004) 2613-2621
27. Zometa (zoledronic acid) concentrate for intravenous infusion [package insert] (2005), Novartis Pharmaceuticals Corporation, East Hanover, NJ